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Introduction: Drug-related hepatotoxicity is a common medical problem with implications for health systems. It
constitutes a cause of acute liver failure and, in many cases, is responsible for the rejection of new pharmacological
agents during efficacy and safety studies. Risk factors, as well as pathogenesis of drug-induced liver injury, are
poorly understood. The diagnosis of drug-induced liver injury is challenging; it is difficult to define the cause of
drug hepatotoxicity due to the heterogeneity of the clinical presentation and the absence of established criteria for
accurate and reproducible identification of drug-associated liver toxicity.
Case presentation: We report the case of a 25-year-old Hispanic woman admitted to our Clinical Hepatology Unit
with symptoms of acute hepatitis of unknown etiology. She was diagnosed with albendazole-induced granulomatous
hepatitis after ruling out other possible causes, based on laboratory studies, liver biopsy, medical history, detailed drug
history, and spontaneous improvement of her liver biochemical profile after medication withdrawal. This diagnosis was
supported by the Council for International Organizations of Medical Sciences-Roussel Uclaf Causality Assessment
Method, which showed a likely correlation between hepatocellular damage and drug toxicity as the etiology.
Conclusions: Our patient’s suspected diagnosis was albendazole-induced granulomatous hepatitis with confirmatory
histologic pattern. This case deserves particular attention due to the wide use of albendazole in our country (Colombia)
and the prevalent medical issue of drug-related hepatotoxicity.
Keywords: Albendazole, Drug-induced liver injury, Granulomatous hepatitis, Idiosyncratic hepatotoxicityIntroduction
Granulomatous hepatitis is a difficult disease to diag-
nose. The etiology of these lesions is rarely determined
histologically, and the presence of granulomas in the
liver does not necessarily imply a granulomatous
process. The lesion pattern is a granulomatous inflam-
matory reaction with the formation of chronic granu-
lomas, composed of aggregates of cells, epithelioid
macrophages arranged in a collar surrounded by mono-
nuclear cells and occasional plasma cells. The etiology is
usually infectious (tuberculosis, brucellosis, fungal or
parasitic), but may also develop in autoimmune disease,
such as primary biliary cirrhosis and rheumatic fever, as
well as having an unknown origin, such as sarcoidosis,* Correspondence: marinji@hotmail.com
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distribution, and reproduction in any mediumor foreign body reaction in response to drug-induced
toxicity [1,2].
In order for a drug to be responsible for granuloma-
tous hepatitis and make a definitive diagnosis of drug-
induced liver injury (DILI), it is necessary to exclude
other causes and demonstrate the improvement of the
condition after stopping the offending drug [1]. Histo-
logically, drug-induced hepatic granulomas are indistin-
guishable from those produced by other causes [3].
Patients usually present with symptoms such as fever,
arthralgia, nausea, and vomiting in the month following
drug initiation, although the symptoms may be delayed.
Physical examination shows the presence of jaundice
and hepatomegaly. Liver function tests show abnormal-
ities of transaminases and alkaline phosphatase. The
presence of hyperbilirubinemia and peripheral blood eo-
sinophilia are not seen in all patients but, when present,
suggest drug-induced hepatitis [1].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Laboratory tests
Test Baseline At 2 months At 6 months
Hemoglobin (g/dL) 12.7 12.0 13.0
Hematocrit (%) 44 43 42
Leukocytes (cells/mm3) 8.400 7.650 7.990
Blood Platelets (platelets/mm3) 140.000 250.000 180.000
Eosinophils (eos/mm3) 260 300 310
Total bilirubin (mg/dL) 13.75 1.1 1.2
Direct bilirubin (mg/dL) 13.66 0.4 0.6
Aspartate aminotransferase (U/L) 933 22 30
Alanine aminotransferase (U/L) 1649 23 31
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the diagnosis of toxic hepatitis. The most widely used
scale is the Council for International Organizations of
Medical Sciences (CIOMS)-Roussel Uclaf Causality As-
sessment Method (RUCAM), developed in 1995, which
relates a causative agent and toxic liver damage, and has
the following results: “highly probable”, “probable”, “pos-
sible”, “unlikely”, or “excluded”, according to the total
score. This method has proven to be more accurate and
reproducible compared with other methods published in
the literature [4-6].
This article describes the case of a patient with
albendazole-induced granulomatous hepatitis with con-
firmatory histologic pattern. This case deserves special
attention due to the wide use of albendazole for the
treatment of Ascaris lumbricoides and other helminth
infections, sometimes without medical prescription in
our country (Colombia). In the literature, there are few
reports of granulomatous hepatitis associated with this
group of drugs.
Case presentation
This case report describes a 25-year-old Hispanic
woman, without significant past medical history, who
presented with progressive jaundice, associated with
right upper quadrant pain, fatigue, weakness, dark urine,
without acholia, fever, or vomiting. On physical examin-
ation, the patient had icteric sclerae, no hepatomegaly
and no stigmata of chronic liver disease. The laboratory
results are shown in Table 1. The results of ultrasonog-
raphy of the liver and biliary tract were normal.
With the clinical and laboratory diagnosis, a prelimin-
ary diagnostic approach to acute hepatitis of unclarified
etiology was established. We performed a percutaneous
liver biopsy guided by ultrasound, which showed portal
inflammatory infiltrate of lymphocytes, plasma cells and
neutrophils, with necrosis of the hepatocytes of the lim-
iting plate, and macrophage infiltrate composed of epi-
thelioid granulomas, forming a non-necrotizing aspect
in the hepatic sinusoids (Figures 1 and 2). Special stains
for tuberculosis and fungi were negative. Contrasted
computed tomography of the chest and abdomen were
normal, ruling out sarcoidosis. The patient had a favor-
able outcome, with gradual improvement of her liver
biochemical profile, without any specific treatment. At
this point, we considered the possibility of drug-related
granulomatous hepatitis. A more detailed questioning
revealed that 2 weeks before the jaundice, the patient
had received empirical treatment with albendazole and
paracetamol and hyoscine butyl bromide for nonspecific
gastrointestinal symptoms. The stool specimen was
normal.
The self-limiting condition, as well as the gradual
normalization in her liver profile, supported thepossibility of toxic hepatitis. Patient monitoring without
any intervention was decided. Table 1 shows some of the
follow-up analysis after 2 and 6 months. The results
demonstrated spontaneous resolution of toxic granu-
lomatous hepatitis.Discussion
Drug-related hepatotoxicity is a common medical prob-
lem, with implications for health systems, and is also a
cause of acute liver failure and, in many cases, respon-
sible for the elimination of new pharmacological agents
during efficacy and safety studies. Risk factors and
pathogenesis of DILI are poorly understood. The diagno-
sis of DILI is one of exclusion, because it is not easy to
define a toxic etiology as the cause of liver disease due
to the heterogeneity of the clinical presentation and evo-
lution. It can range from transient elevations in liver en-
zymes to liver failure and even symptomatic chronic
liver disease [3,7].
Figure 1 Hematoxylin and eosin stain. Portal tracts infiltrate with moderate and mixed inflammation, consisting of lymphocytes, plasma cells,
neutrophils, and eosinophils with moderate interface activity. Inflammatory Activity Grade 3 to 4.
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nervous system action, herbal supplements, and immu-
nomodulatory agents are the most common cause of
DILI in the United States of America. Hepatocellular in-
jury patterns are more common in younger patients,
whereas patterns of cholestasis prevail in older patients
[3,5,7]. These findings are consistent with those found in
other studies where antibiotics, nonsteroidal anti-
inflammatory drugs, and immunomodulatory drugs have
been implicated as a cause of drug-induced hepatotox-
icity [6,8-10]. However, acute liver failure is rare, and up
to 17% of cases are attributed to idiosyncratic reactions,
determined by individual susceptibility and not related
to the dose of the drug. There are no models for
predicting adverse reactions [9,11].
The Naranjo Probability Scale and Clinical Diagnostic
Scale are also used to assess the causality of drug-
induced hepatotoxicity [6]. The CIOMS-RUCAM scale
showed a “possible” relationship with a score of fiveFigure 2 Hematoxylin and eosin stain. Hepatic parenchyma with
presence of epithelioid macrophages that have formed granulomas
without necrosis, interspersed with lymphocytes. Inflammatory
activity around the granulomas is characterized by inflammatory
lobular cells between the sinusoids and hepatocytes.points, which supported the diagnosis of albendazole-
induced granulomatous hepatitis with a pattern of hepa-
tocellular DILI damage. The clinical and biochemical
improvement of the patient after stopping the medica-
tion, without recurrence, confirms the diagnosis [4-6].
In clinical trials, treatment with albendazole has been
associated with mild to moderate elevations of liver en-
zymes in about 16% of patients. Although generally
returned to normal after discontinuation of treatment,
there have been reports of persistent hepatitis [12].
At the time of this review, only three articles were
indexed in MEDLINE: the first describes a case of
granulomatous hepatitis induced by mebendazole ad-
ministration in a patient with cytolytic hepatitis with eo-
sinophilia to treat infestation Ascaris in the presence of
fever, diarrhea, and eosinophilia. Liver biopsy results
were consistent with the diagnosis of granulomatous
hepatitis [2]. Another report in the literature describes
the case of a patient who had consumed albendazole 6
hours earlier, and for whom alterations in liver function
tests, necrosis, and steatosis characteristics of hepatocel-
lular hepatitis were documented [12]. The diagnosis of
drug-induced hepatitis or DILI was based also on the
evaluation method CIOMS-RUCAM, with a score of
nine (“highly probable”) [4]. The exclusion of other pos-
sible causes and spontaneous liver profile improvement
also supported this diagnosis.
The third case reported acute hepatitis with jaundice
and slightly elevated liver function tests in a 7-year-old
patient after administration of oral albendazole [13].
This side effect has been known after prolonged admin-
istration, but as far as it is known, acute hepatitis has
never been described in infants.
Compared to the case presented in the reports men-
tioned above, the diagnosis in these reports was
conducted by history of ingestion of an antiparasitic
agent and the presence of eosinophilia, the difference
with the case presented relied on the presence of fever
and the period of time until symptoms developed.
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hepatocellular, cholestatic, and combined, according to
the levels of liver enzymes [12]. In the reports men-
tioned above, there were established hepatocellular dam-
age patterns and granulomatous reactions, as in the case
presented. In our case, the positivity of anti-smooth
muscle antibodies could be explained by a false positive
due to hepatocellular necrosis. A subsequent review
of all autoimmune markers indicated that these were
negative. The clinical presentation of this case is un-
specific, but it is consistent with other reported cases
of DILI [2,12,13].
In many countries, the health system must be advised
of the importance of controlling the sale of “over-the-
counter” drugs, including antibiotics, in order to avoid
unnecessary hepatotoxicity.
Conclusions
This case illustrates how albendazole-induced granu-
lomatous hepatitis, although rare, should be considered
in patients in whom other causes have been excluded,
thus presenting resolution of symptoms after medication
withdrawal. The initial clinical presentation of this pa-
tient, laboratory findings, previous use of albendazole,
and self-limiting condition with a gradual normalization
of liver profile after removal of the drug, supported the
possibility of toxic hepatitis. The diagnosis of DILI is
one of exclusion, because it is not easy to define a toxic
etiology as the cause of liver disease due to the hetero-
geneity of the clinical presentation and evolution. The
CIOMS-RUCAM scale showed a “possible” relationship
with a score of five, which supported the diagnosis of
albendazole-induced granulomatous hepatitis with a pat-
tern of hepatocellular damage. This case deserves special
attention due to the wide use of albendazole in our
country and because drug-related hepatotoxicity is a fre-
quent medical problem.
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